Showing 6001-6010 of 21466 results for "".
- Decoding MASLD: The Role of Biomarkers in Liver Disease Managementhttps://reachmd.com/news/decoding-masld-the-role-of-biomarkers-in-liver-disease-management/2483565/In the rapidly changing landscape of metabolic liver diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is now recognized under updated nomenclature as a major clinical category within metabolic liver disease. Clinicians are increasingly relyi
- Positioning Psoriatic Disease in Global Health Policy: A Call to Actionhttps://reachmd.com/news/positioning-psoriatic-disease-in-global-health-policy-a-call-to-action/2483554/Psoriatic disease is increasingly capturing necessary attention in global health policy discussions. Its far-reaching systemic impacts, traditionally marginalized in the narrative of noncommunicable diseases (NCDs), are now demanding inclusion and recognition. Current initiatives un
- Roflumilast Phase 2 Results for Children Consistent With Phase 3 Adult Trialshttps://reachmd.com/news/roflumilast-phase-2-results-for-children-consistent-with-phase-3-adult-trials/2483558/Once-daily roflumilast cream 0.3% was well tolerated and improved signs and symptoms of psoriasis in children 2 to 11 years old in two 4-week, phase 2, open-label, maximal usage pharmacokinetic and safety studies, according to an article published in Pediatric Dermatology. The res
- Evolving Cardiovascular Risks: Addressing Today's Clinical Challengeshttps://reachmd.com/news/evolving-cardiovascular-risks-addressing-todays-clinical-challenges/2483547/The landscape of cardiovascular risks is shifting significantly, presenting both challenges and opportunities for innovation in public health. In the U.S., based on national surveillance estimates from recent years, about
- Bridging the Global Oncology Gap: Navigating Cancer Trends and Misinformationhttps://reachmd.com/news/bridging-the-global-oncology-gap-navigating-cancer-trends-and-misinformation/2483544/Annual global cancer deaths are projected to exceed 18 million by 2050, according to international modeling. Managing rising cancer rates demands urgen
- CHLA Highlights at the 2025 American Academy of Pediatrics Conferencehttps://reachmd.com/news/chla-highlights-at-the-2025-american-academy-of-pediatrics-conference/2483513/Children’s Hospital Los Angeles (CHLA), one of the nation's top pediatric academic institutions, will once again take center stage at th
- Pediatric Septic Shock Management: The Role of Hemodynamic Ultrasoundhttps://reachmd.com/news/revolutionizing-pediatric-shock-management-the-role-of-hemodynamic-ultrasound/2483543/In pediatric critical care, hemodynamic point-of-care ultrasound (POCUS)—also termed functional echocardiography—stands out as a valuable adjunct, helping refine timely interventions and support clinical decision-making within pediatric septic shock care, while guidelines position it as a c
- Harnessing AI for Early Asthma Risk Prediction in Children: A New Frontier in Pediatric Carehttps://reachmd.com/news/harnessing-ai-for-early-asthma-risk-prediction-in-children-a-new-frontier-in-pediatric-care/2483524/Asthma in children poses a significant challenge to clinicians worldwide. Traditional methods of predicting asthma risks are being revolutionized by artificial intelligence (AI), unlocking new possibilities for personalized pediatric care while also surfacing the central tension: prediction
- Uncorking the Truth: Reevaluating Alcohol Consumption and Dementia Riskhttps://reachmd.com/news/uncorking-the-truth-reevaluating-alcohol-consumption-and-dementia-risk/2483531/Can a single drink quietly tip the scales toward dementia? As new research is surfacing, the potential risks of even moderate alcohol consumption on cognitive health are coming into sharper focus, challenging traditional wisdom. While risk may increase even at low levels, public health guid
- Ocrelizumab: Leading the Charge in MS Relapse Managementhttps://reachmd.com/news/ocrelizumab-leading-the-charge-in-ms-relapse-management/2483527/In the dynamic landscape of multiple sclerosis (MS), managing relapses represents an ever-present challenge, as reflected in major society recommendations for disease-modifying therapy in relapsing forms of MS. Ocrelizumab is carving out its place as a pivotal player in this arena, promisin